Binding characterization of [3H]s-0139, an antagonist of the endothelin ET(A) receptor subtype

European Journal of Pharmacology

Volumn 342, Issue 2-3, 1998, Pages 319-324

  Mihara, Shin Ichi ^a   Tozawa, Fumiyo ^a   Itazaki, Kohji ^a   Fujimoto, Masafumi ^a  

^a SHIONOGI AND CO LTD   (Japan)

Author keywords

Endothelin; Endothelin ET(A) receptor; Receptor antagonist; S 0139; Smooth muscle, aortic

Indexed keywords

27 O 3 [2 (3 CARBOXYACRYLOYLAMINO) 5 HYDROXYPHENYL]ACRYLOYLOXY MYRICERONE; CALCIUM ION; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST; RECEPTOR SUBTYPE; UNCLASSIFIED DRUG; 27 O [3 [2 (3 CARBOXYACRYLOYLAMINO) 5 HYDROXYPHENYL]ACRYLOYLOXY]MYRICERONE; CAFFEIC ACID DERIVATIVE; CALCIUM; DIAGNOSTIC AGENT; DRUG DERIVATIVE; ENDOTHELIN; ENDOTHELIN RECEPTOR; MYRICERIC ACID A; OLEANOLIC ACID; RADIOACTIVE IODINE; TRITERPENE;

ANIMAL CELL; ANIMAL TISSUE; AORTA MEDIA; ARTICLE; BINDING AFFINITY; BINDING SITE; CALCIUM MOBILIZATION; CHO CELL; NONHUMAN; PRIORITY JOURNAL; RAT; SMOOTH MUSCLE FIBER MEMBRANE; SWINE; ANIMAL; COMPARATIVE STUDY; CYTOSOL; DRUG ANTAGONISM; IN VITRO STUDY; METABOLISM; THORACIC AORTA; VASCULAR SMOOTH MUSCLE;

ANIMALS; AORTA, THORACIC; CAFFEIC ACIDS; CALCIUM; CYTOSOL; ENDOTHELINS; IODINE RADIOISOTOPES; MUSCLE, SMOOTH, VASCULAR; OLEANOLIC ACID; RECEPTORS, ENDOTHELIN; SWINE; TRITERPENES;

EID: 0032567541     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(97)01479-9     Document Type: Article

References (20)

1. Clozel M., Breu V., Gray G.A., Kalina B., Loffler B.-M., Burri K., Cassal J.-M., Hirth G., Muller M., Neidhart W., Ramuz H. Pharmacological characterization of Bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. J. Pharmacol. Exp. Ther. 270:1994;228-235.
2. Doherty A.M. Design and discovery of nonpeptide endothelin antagonists. Drug Discovery Today. 1:1996;60-70.
3. Elshourbagy N.A., Lee J.A., Korman D.R., Nuthalaganti P., Sylvester D.R., Dilella A.G., Sutiphong J.A., Kumar C.S. Molecular cloning and characterization of the major endothelin receptor subtype in porcine cerebellum. Mol. Pharmacol. 41:1992;465-473.
4. Fujimoto M., Mihara S., Nakajima S., Ueda M., Nakamura M., Sakurai K. A novel non-peptide endothelin antagonist isolated from bayberry, Myrica cerifera. FEBS Lett. 304:1992;41-44.
5. A receptor. Life Sci. 50:1992;247-255.
6. Ishikawa K., Ihara M., Noguchi K., Mase T., Mino N., Saeki T., Fukuroda T., Fukami T., Ozaki S., Nagase T., Nishikibe M., Yano M. Biochemical and pharmacological profile of a potent and selective endothelin B-receptor antagonist, BQ788. Proc. Natl. Acad. Sci. USA. 91:1994;4892-4896.
7. Maguire J.J., Bacon C.R., Fujimoto M., Davenport A.P. Myricerone caffeoyl ester (50-235) is a non-peptide antagonist selective for human ETA receptors. J. Hypertens. 12:1994;675-680.
8. A receptor-specific effect of 50-235, a nonpeptide endothelin antagonist. Eur. J. Pharmacol. Mol. Pharmacol. 246:1993;33-38.
9. 3H ]U46619 binding in pig aorta smooth muscle membranes Eur. J. Pharmacol. 151:1988;59-65.
10. 2+ increases in vascular smooth muscle cells. FEBS Lett. 259:1989;79-82.
11. A receptor antagonist, 50-235, and its derivatives. Eur. J. Pharmacol. Mol. Pharmacol. 247:1993;219-221.
12. Mihara S., Nakajima S., Matsumura S., Konoike T., Fujimoto M. Pharmacological characterization of a potent nonpeptide endothelin receptor antagonist, 97-139. J. Pharmacol. Exp. Ther. 268:1994;1122-1128.
13. B receptors. J. Pharmacol. Exp. Ther. 271:1994;755-761.
14. Rubanyi G.M., Polokoff M.A. Endothelins: Molecular biology, biochemistry, pharmacology, physiology and pathophysiology. Pharmacol. Rev. 46:1994;325-415.
15. Sakurai T., Yanagisawa M., Masaki T. Molecular characterization of endothelin receptors. Trends Pharmacol. Sci. 13:1992;103-108.
16. Sakurawi K., Yasuda F., Tozyo T., Nakamura M., Sato T., Kikuchi J., Terui Y., Ikenishi Y., Iwata T., Takahashi K., Konoike T., Mihara S., Fujimoto M. Endothelin receptor antagonist triterpenoid, myriceric acid A, isolated from Myrica cerifera, and structure activity relationships of its derivatives. Chem. Pharm. Bull. 44:1996;343-351.
17. Walsh T.F. Progress in the deveropment of endothelin receptor antagonists. Annu. Rep. Med. Chem. 30:1995;91-100.
18. A subtype. Drug News Perspect. 9:1996;348-350.
19. Yanagisawa M. The endothelin system. A new target for therapeutic intervention. Circulation. 89:1994;1320-1322.
20. Yanagisawa M., Kurihara H., Kimura S., Tomobe Y., Kobayashi M., Mitsui Y., Yazaki Y., Goto K., Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 332:1988;411-415.